Summit Therapeutics SMMT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $619.03M+262% | $537.67M+257% | $441.76M+256% | $348.39M+242% | $171.17M+113% | ||
| $603.76M+839% | $556.75M+825% | $493.35M+772% | $410.89M+894% | $64.28M+90.0% | ||
| $1.22B+388% | $1.09B+384% | $935.11M+378% | $759.28M+380% | $250.46M+119% | ||
| $16.69M+9.3% | $14.84M+11.0% | $13.51M-46.1% | $15.67M-20.5% | $15.27M-17.2% | ||
| -$1.21B-401% | -$1.08B-388% | -$921.62M-369% | -$746.08M-361% | -$240.76M-108% | ||
| -$1.59-354% | -$1.44-350% | -$1.25-421% | -$1.02-437% | -$0.35-192% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Summit Therapeutics profitable?
- Summit Therapeutics is not currently profitable: it reported a net loss of $1.2B over the trailing twelve months, a -271685.0% net margin.
- What is Summit Therapeutics's earnings per share?
- Summit Therapeutics's diluted EPS over the trailing twelve months is $-1.59.
- Where does Summit Therapeutics's income statement data come from?
- Every line is extracted from Summit Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.